FDA warns Indelicare that its INKEEZE lidocaine numbing gel, spray and foam soap are unapproved new drugs sold outside OTC limits.
What happened
FDA reviewed the company's website in November 2023 and found three INKEEZE products sold as numbing products for use before, during and after tattooing and other cosmetic procedures. FDA said the gel and spray contain 5% lidocaine, above the 0.5% to 4% range allowed for over-the-counter external pain relievers, and that tattooing claims are not covered by the OTC rules for these products. FDA noted that as of March 22, 2024 the products were no longer on the company's website but could still be bought from third-party online sellers.
What FDA found
The three products are unapproved new drugs because they do not meet the conditions for legal over-the-counter marketing.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The gel and spray contain 5% lidocaine, above the 0.5% to 4% range the OTC external analgesic order allows.
Section 505G, 21 U.S.C. 355h; OTC Monograph M017The labels and website claim the products relieve pain from tattooing, an use not allowed for these OTC products.
Section 505G, 21 U.S.C. 355h; OTC Monograph M017The gel and spray are also labeled for hemorrhoid use, but at 5% lidocaine they cannot meet the rules for both external pain relievers and hemorrhoid products.
OTC Monograph M015; Section 505G, 21 U.S.C. 355hThe foam soap claims to reduce bacteria on skin but does not meet the OTC requirements for antiseptic products.
Section 505G(a)(3) of the FD&C ActThe products are misbranded (mislabeled in FDA's terms) because they are nonprescription drugs that do not follow section 505G and have no approved application.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
What FDA wants
FDA asks the company to write within fifteen working days describing the specific steps taken to fix the violations, how it will prevent them from happening again, and copies of related records. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.
Who should pay attention
- tattoo studios and artists who apply numbing products before sessions
- online retailers and distributors still selling INKEEZE numbing products
- other makers of lidocaine numbing products marketed for cosmetic procedures
This is a summary. Read the original letter on fda.gov.